Ad
related to: pombiliti opfolda fda approval
Search results
Results from the WOW.Com Content Network
Cipaglucosidase alfa, sold under the brand name Pombiliti, and used in combination with miglustat, is a medication used for the treatment of glycogen storage disease type II (Pompe disease). [ 4 ] [ 5 ] Cipaglucosidase alfa is a recombinant human acid α-glucosidase enzyme replacement therapy that provides an exogenous source of acid α ...
In September 2023, the FDA approved a two-component therapy of Pombiliti (cipaglucosidase alfa-atga) and Opfolda 65 mg capsules for adults living with late-onset Pompe disease weighing more than 40 kg and who are not improving on their current enzyme replacement therapy. [19] [20]
Miglustat is indicated to treat adults with mild to moderate type I Gaucher disease for whom enzyme replacement therapy is unsuitable. [14]In the European Union, miglustat (Opfolda), in combination with cipaglucosidase alfa, is a long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α‑glucosidase [GAA] deficiency).
The warning, set off in a blue box, on an FDA page concerning the study of sex differences in the clinical evaluation of medical products goes on to say, “The Trump Administration rejects gender ...
As with any prescription drug, they should only be used as needed. This is especially true for antibiotics, as unnecessary use can slowly make bacteria more resistant to these drugs. Common side ...
Robert F. Kennedy Jr.'s confirmation hearing on Wednesday to lead the Department of Health and Human Services saw senators question the environmental lawyer about his views on vaccines, abortion ...
In combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant ...
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's what a doctor wants you to know.
Ad
related to: pombiliti opfolda fda approval